Arrowehead Nanotechnologietitel mit gigantischem Potential - 500 Beiträge pro Seite

[Nanostart]

Arrowehead ist eine Amerikanische Beteiligungsfirma mit sehr aussichtsreichen Firmenbeteiligungen.Diese Firma gab Gestern bekannt, dass die Firma Unidym an denen sie die Mehrheit besitzen sich mit der amerikanischen Firma Carbon Nanotech inc. verschmolzen hat. Die zukünftige weiterarbeit wird unter dem Namen Unidym fortgeführt.
Carbon Nanotech ist eine der aussichtsreichsten Nanofirmen in den USA. Carbon Nanotech Inc. besitzt weit über 100 Patente im Bereich neuer Materialien. Diese Materialien sollen nach verschiebung einiger Atome eine 100 mal festere Härte als Stahl haben, die Leitfähigkeit von Kupfer besitzen und die Thermischen Fähigkeiten von Diamanten besitzen. Die Anwendungsgebiete von solchen Materialien sind unglaublich. Sicherlich ist in diesem Bereich noch extrem viel Foschung notwendig, aber wer von Anfang an dabei sein will sollte sich wohl einige Stücke ins Depot legen. Ich hatte Glück und habe mit eher zufällig vor ein paar Tagen einige Stücke gekauft. Falls jemand weis welche Firmaen noch zu den Beteiligungen von Arrowehead gehören oder falls jemand Arrowehead schon länger auf seiner Watchliste hat, für Infos bin ich immer dankbar.

[schlumpfdipumpf]

hast mal ein Kürzel oder eine WKN...hab bei Yahoo nix gefunden...

Würd ich mir gerne mal näher ansehen...

Vielen Dank

[Nanostart]

A0CA96 dies ist die WKN Nummer von Arrowehead research.
Du kannst bei Google Arrowehead research eingeben und anschl. findest du unter diesem Namen unter News die Infos von gestern und der Vergangenheit.

[JuppSchmitz]

HALLO! Ist zwar in englisch, aber hoffentlich trotzdem hilfreich.

Arrowhead Research Corporation engages in the identification, development, and commercialization of nanotechnology-related products and applications in the United States. The company, through its subsidiary, Insert Therapeutics, Inc., developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Its product IT-101, an anti-cancer drug candidate is under Phase I clinical trials. The company, through its subsidiary, Calando Pharmaceuticals, Inc., focuses on the design, development, and commercialization of novel RNAi therapeutics to treat diseases and other medical conditions by combining RNAi therapeutics with patented and proprietary delivery technologies. Its CALAA-01 product is a formulation containing Calando?s proprietary delivery technology with a siRNA duplex targeting the M2 subunit of ribonucleotide reductase. Arrowhead Research Corporation, through its other subsidiary, Unidym, Inc., also focuses on the application of carbon-based materials, such as touch screens, flat panel displays, and solid state lightings to the electronics industry. In addition, the company, through its other subsidiary, Aonex Technologies, Inc., is developing semiconductor nanomaterials, such as engineered wafers that comprise thin films of materials suitable for LED fabrication. It has a collaboration agreement with R&D-Biopharmaceuticals GmbH to develop and commercialize conjugates of the potent anti-cancer compound tubulysin. Arrowhead Research Corporation was founded in 2003 and is headquartered in Pasadena, California.

Hier noch der Link zur Website:
http://www.arrowres.com/

Ich wünsche ein schönes Wochenende.

[Nanostart]

Guten Morgen,

auf in eine weitere hoffendlich erfreuliche Woche.
Ich habe mir das Buch von Marco Beckmann "Nano-Stocks" gekauft und über das WE gelesen. Das Buch ist im Jahr 2004 auf den Markt gekommen.
Es werden unter anderem viele Firmen vorgestellt. Inhalt: Führung der Unternehmen, Forschungsinhalte, Visionen, Kooperationspartner und natürlich auch sehr verständlich für uns Laien geschrieben welches Potential in verschiedenen Firmen steckt. Welches Potential überhaupt der Markt bietet. Unter anderem auch die Firma Carbon Nanotech Inc. (CNI). Meiner Einschätzung nach kommt man (wenn man schon in Nanotech investiert) nicht an Arrowehead und somit an (CNI) und Unidym vorbei. Ich denke wir alle hier im Forum Nanotechnologie wissen über die Risiken bescheid.
Weitere Firmen die in diesem Buch erwähnt sind finde ich ebenfalls sehr interessant. Z.B. Biodilivery oder Arqule. Kann ja jeder mal im Netz schauen on diese Nanofirmen ihm zusagen.
Weiter habe ich noch einmal die aktuellen News von letzter Woche.
Ich möchte diesen Wert nicht pushen, da ist mir nichts dran gelegen.
Arrowehead ist nur ein kleiner Bestandteil meines Depots. Ich habe mir ein Nanodepot zugelegt das weitere interessante Werte beinhaltet

Also viel Spass beim lesen!

Arrowhead Research Corporation (Nachrichten) (NASDAQ:ARWR) announced today that its majority-owned subsidiary, Unidym, Inc., has entered into a definitive agreement to merge with Carbon Nanotechnologies, Inc. (“CNI“). The transaction is expected to close in early April. The combined company, which will operate under the Unidym name, will have the dominant portfolio of carbon nanotube-related patents and be positioned as a leader in bringing carbon nanotube-based products to market.

“CNI is the largest manufacturer of carbon nanotubes in the world and has hundreds of customers, in addition to partnerships and licensing arrangements with companies like Motorola, Sumitomo, IBM, DuPont, and Johnson Matthey,“ said R. Bruce Stewart, Arrowhead's Chairman. “We believe this deal is transformational for the industry and will enable more rapid commercialization of products incorporating nanotubes since so much of the intellectual property can now be licensed from one company.“

CNI was founded in 2000 by the late Rice University professor Richard Smalley who received the Nobel Prize for his work in carbon nanotubes. His pioneering work led to a suite of patents that covers technologies being used today to develop nanotube-based products. CNI has more than 100 patents (including 54 issued U.S. patents) and patent applications covering compositions of matter, methods of manufacturing, processing and products incorporating carbon nanotubes, with over 5000 claims in various stages of prosecution.

“We chose Unidym as our partner because Unidym has the most advanced carbon nanotube-based electronic products with billion dollar market potential, as well as an impressive carbon nanotube patent portfolio of its own,“ said Bob Gower, CEO of Carbon Nanotechnologies, Inc.

Unidym, founded by distinguished UCLA professor Dr. George Gruner, is developing carbon nanotube-based products for the electronics industry. The company's first product is a transparent electrode that is intended to replace the indium tin oxide (ITO) electrodes in products such as flat-panel displays used in televisions, laptop computers, mobile phones and touch screens, solar cells, and solid state lighting. The total existing market for this product is approximately $1 billion. Unidym has already provided samples to potential customers in each of its target industries. Unidym's second product is a carbon nanotube-based thin film transistor (TFT) intended for the emerging flexible (also known as printable) electronics industry.

“Unidym now has critical mass,“ stated Sean Olson, President of Unidym. “Unidym will use its expansive patent portfolio to protect its first three products -- transparent electrodes, fuel cell electrodes, and thin film transistors -- and to immediately pursue licensing opportunities for a range of other nanotube-based products such as targeted therapeutics, medical devices, field emission displays, batteries, sporting goods and composite materials.“

Upon closing, Arrowhead will retain majority-ownership of Unidym. Under the terms of the definitive agreement, all outstanding shares of capital stock of CNI will be converted into shares of Series A Preferred Stock of Unidym. In connection with the merger, Arrowhead will exchange $5.4 million worth of Arrowhead common stock for Series E preferred stock in CNI prior to the closing of the merger. In addition, Arrowhead is transferring to Unidym the rights and obligations of its research agreement with Duke University and the University of Florida and Arrowhead will accelerate $4 million of future capital contributions to Unidym on the closing date.

Arrowhead Research Corporation () is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Unidym

Unidym, Inc. is developing low-cost, carbon-based materials, processes, and devices for the electronics industry. The Company's initial product is a thin, transparent film of carbon nanotubes that replaces the expensive, failure-prone materials currently employed by manufacturers of devices such as touch screens, flat panel displays, and solid state lighting. Unidym is also developing novel carbon nanotube-based transistors and conductive inks for the printable electronics industry to replace today's complex and capital intensive semiconductor manufacturing processes with inexpensive, solution-based printing processes. Unidym differentiates itself through its emphasis on low-cost materials and processes, in-house carbon nanotube production, aggressive partnership strategy, and significant intellectual property portfolio that includes foundational IP in both of its initial applications.

About Carbon Nanotechnologies, Inc.

CNI has more than 100 patents and patent applications with a total of about 5000 claims in various stages of prosecution. The portfolio of 100 patents and applications includes about 850 composition of matter claims. CNI has several pilot plants to produce single-wall and other small-diameter carbon nanotubes in operation at its location in west Houston.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[JuppSchmitz]

Auch im medizinischen Bereich sind die mittlerweile aussichtsreich positioniert.

Ich wünsche allen eine schöne Woche.


Arrowhead to Form New Nanomedicine Subsidiary and Acquire Nanotherapeutics Company, C Sixty, Inc.
Monday March 26, 7:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that it has formed a new wholly-owned subsidiary and has agreed to acquire the assets, as well as the name, of C Sixty, Inc. (C-60), a company pioneering the development of new drugs based on buckministerfullerenes (also known as fullerenes or buckyballs).
ADVERTISEMENT


The new subsidiary joins Arrowhead as its third focused on nanomedicine. Arrowhead operates two other majority owned subsidiaries commercializing nanotherapeutics. Calando Pharmaceuticals is a leading RNAi company specializing in the design and delivery of siRNA therapeutics. Insert Therapeutics is commercializing drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Insert's first anti-cancer drug candidate is in Phase I clinical trials.

"The future of medicine lies in targeted delivery of therapeutics through nanotechnology," said R. Bruce Stewart, Arrowhead's Chairman. "Our experience and expertise in this area makes C-60 a great strategic complement to our other majority owned subsidiaries."

Fullerenes are a highly structured, water soluble, nanoscale form of carbon, similar to carbon nanotubes, discovered by Richard Smalley, who received the Nobel Prize for his work in this area. Roughly one nanometer in diameter, the molecules are composed of 60 carbon atoms and have the symmetry of soccer balls. The spherical shape, hollow interior, and 60 carbon atoms of the molecule allow drug designers the opportunity to attach therapeutic and targeting chemical groups in many configurations.

C Sixty, Inc. has secured and developed a strong patent position covering the strategic biomedical uses of fullerenes. Initially, C-60 will focus on the antioxidant activity of fullerenes. Arrowhead believes that drugs based on fullerene antioxidant molecules may have significant impact on several unsolved diseases, including Parkinson's disease, Alzheimer's, stroke, atherosclerosis, complications from diabetes and protection of bone marrow cells from cancer chemotherapy and radiotherapy. Solutions for any of these diseases could represent billion dollar annual market opportunities.

[Nanostart]

Sehr Gut! Die News sind ja von Heute.

Na, dann bin ich ja mal auf Heute Nachmittag gespannt, denn in den USA werden die Kurse gemacht.

Danke für die Infos!!

[Nanostart]

Guten Tag und Hallo,

am 20.04.2007 wird auf dem Sender "3 Sat" (Das Thema: 3 Sat Börse) die Nanotechnologie sein.

Bin mal gespannt welche Unternehmen vorgestellt werden.
Vielleicht ist Arrowehead, Nanostart, Obducat, BioSante, Biodilivery, oder Arqule dabei.
Vielleicht auch Unternehmen die weniger bekannt sind.

Die bekanntesten die bereits eine relativ hohe Marktkapitalisierung besitzen wie: Headwaters oder Flamel werden wohl auch erwähnt werden.

Also schön den Fernseher einschalten und gucken! Vielleicht gibt es nach dem Bericht am darauffolgendem Montag ein paar Prozente!?

[BERNDDD]

Danke für den Tip, werd ich mir ansehen..........
hat heut jemand die Sendung
"2057- unser Leben in der Zukunft" gesehen?
Ein Fahrstuhl ins All, dank Nanoseilen und
der neue Kampfanzug für die US Army.
Ist schon Wahnsinn, was da auf uns zurollt.

[Nanostart]

Guten Morgen Bernddd,

so ein Ärger, ich hatte mir fest vorgenommen, diese Sendung zu sehen. Genau das Thema hätte mich besonders interessiert. Weil: Materialien fester als Stahl und leichter als Papier usw. Visionen die begeistern und, und, und.

Es war sicherlich sehr spannend.

Naja verpasst.

Also eine angenehme Börsenwoche!! Trotz schlecht ausgefallenem Tankan Bericht.

[Nanostart]

03.04.2007 13:22
Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

Arrowhead Research Corporation (Nachrichten) (NASDAQ: ARWR) announced the publication by its majority-owned subsidiary Calando Pharmaceuticals, Inc. of a study demonstrating the anti-proliferative effect of the siRNA sequence selected as the therapeutic component of its lead anti-cancer compound, CALAA-01.

The paper, entitled “Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo“, was published in Clinical Cancer Research, a journal published by the American Association of Cancer Research (AACR). This paper describes how Calando's proprietary siRNA duplex demonstrated silencing of the target gene, RRM2, and reduced cell proliferation across multiple species and cancer types, both in cell culture and in whole animals. These findings confirm that this duplex is a promising candidate for therapeutic development.

“The paper reports some of the great progress being made at Calando,“ said R. Bruce Stewart, Chairman and CEO of Arrowhead. “We believe that siRNA will be one of the corner stones of cancer treatment in the future“.

“These studies demonstrate the potential for this siRNA duplex to have a strong anti-tumor effect,“ said John Petrovich, Calando's Chief Executive Officer. He further added that Calando has filed for patent protection on several siRNA duplexes against the RRM2 target and has licensed patents from Alnylam Pharmaceuticals to enable it to develop and commercialize an RNAi therapeutic against this target.

Further information about Calando can be found at www.calandopharma.com.

Arrowhead Research Corporation () is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Calando Pharmaceuticals Inc.

Calando Pharmaceuticals Inc. (www.calandopharma.com), a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to design and create new, targeted siRNA therapeutics. The company is pursuing this goal through its internal research and development and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Calando Technology

Calando's cyclodextrin-containing polymers form the foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic “backbone“ of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm in diameter that fully protect the siRNA from nuclease degradation in serum. The siRNA delivery system has been designed to allow for intravenous injection. Upon delivery to the target cell, the targeting ligand binds to membrane receptors on the cell surface and the RNA-containing nanoparticle is taken into the cell by endocytosis. There, chemistry built into the polymer functions to unpackage the siRNA from the delivery vehicle. In addition to targeting tumors, the targeting of liver cells has also been accomplished in vivo.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our latest Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[BERNDDD]

der Chart hier sieht gut aus....
gefällt mir,
auch bei anderen Nanoaktien, das gleiche Bild.
könnte ein schönes Jahr werden

[Nanostart]

Antwort auf Beitrag Nr.: 28.786.669 von BERNDDD am 12.04.07 23:34:34

16.04.2007 13:10
Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert(TM) Drug Delivery System at AACR Meeting

PASADENA, Calif., April 16 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation (Nachrichten) announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc., are presenting data at the 2007 American Association for Cancer Research (AACR) Annual Meeting. The presentations summarize the latest research findings on two anticancer therapies currently under development. Both therapies employ a novel delivery system called Cyclosert(TM), developed at the California Institute of Technology and exclusively licensed to Insert Therapeutics and, through Insert, to Calando.

"We are pleased that our companies have outstanding data to present at this prestigious conference," said R. Bruce Stewart, Chairman and Chief Executive Officer of Arrowhead. "We see great promise going forward for the treatment of cancer using our delivery system."

Cyclosert is the first nanoparticle drug transport platform to be designed de novo and synthesized specifically to overcome limitations in existing technologies used for the systemic transport of therapeutics to targeted sites within the body. Based on small cyclic repeating molecules of glucose called cyclodextrins, Cyclosert promotes the ability of cytotoxic drugs to inhibit the growth of human cancer cells while reducing toxicity and remaining non-immunogenic at therapeutic doses. In particular, the system is designed to reduce the toxicity of the drugs until they actually reach the targeted tumor cells where the active drug is released in a controlled fashion.

Insert's Chief Scientific Officer, Thomas Schluep, Sc.D., will present data from in vitro and animal studies using the Cyclosert system to deliver tubulysin A, a potent, but highly toxic, antitumor agent. In vitro studies have shown the tubulysin-Cyclosert conjugate to be effective against multiple human cancer cell lines. The conjugate was found to be stable and 100 times more water soluble than the free drug.

Calando's Chief Scientific Officer, Jeremy Heidel, Ph.D, will present data from animal studies using the Cyclosert system augmented by Calando's own proprietary technology. Calando is developing a type of ribonucleic acid (RNA) called small interfering RNA, or siRNA, for anticancer use. In the tests, this siRNA-containing formulation, using Cyclosert as a delivery system, showed significant antitumor activity and was well-tolerated.

Testing and development is ongoing for both drugs. About Arrowhead Research Corporation

Arrowhead Research Corporation (http://www.arrowheadresearch.com/) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Insert Therapeutics Inc.

Insert Therapeutics, Inc. (http://www.insertt.com/) is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials -- linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company is pursuing this goal through its internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

About Calando Pharmaceuticals Inc.

Calando Pharmaceuticals Inc. (http://www.calandopharma.com/) is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to design and create new, targeted siRNA therapeutics. Small interfering RNAs (siRNA) use RNA interference, or RNAi, a naturally occurring mechanism within cells to selectively silence and regulate specific genes. The ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. The company is pursuing this goal through its internal research and development and also through collaborations and partnerships with pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our latest Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

[BERNDDD]

Antwort auf Beitrag Nr.: 28.838.016 von Nanostart am 16.04.07 15:32:06

[Nanostart]

Arrowhead Research Says Its Subsidiaries Will Present Data On Two New Anticancer Therapies - Update [ARWR]

4/16/2007 5:10:27 PM Arrowhead Research Corp. (ARWR), a nanotechnology company, on Monday announced that two of its majority owned subsidiaries, Insert Therapeutics, Inc. and Calando Pharmaceuticals will present data on two anticancer therapies currently under development using a new delivery system called Cyclosert at the 2007 American Association for Cancer Research annual meeting.

The company stated that Cyclosert is the first nanoparticle drug transport platform designed to overcome limitations in existing technologies used for transport of therapeutics to target sites within the body. The system is designed to keep the drugs non-toxic until they actually reach the targeted tumor cells where the active drug is released in a controlled manner. Cyclosert promotes the ability of cytotoxic drugs to inhibit the growth of human cancer cells while remaining non-toxic and non-immunogenic at therapeutic doses.

Arrowhead is developing in collaboration with German-based R&D Biopharmaceuticals a potent anticancer agent called tubulysin A. It is highly active against many types of cancer cells, but used by itself is highly toxic. By combining it with the Cyclosert transport system, researchers are aiming to make it non-toxic while preserving its antitumor activity.

Calando's Chief Scientific Officer, Jeremy Heidel, will present data from animal studies using the Cyclosert system augmented by Calando's own proprietary technology. Calando is developing a type of ribonucleic acid or ‘RNA' called small interfering RNA, or siRNA, for anticancer use. In the tests, this siRNA-containing formulation, using Cyclosert as a delivery system, showed significant antitumor activity and was well tolerated, the company added.

"Based on this data, we are very optimistic as we move closer to an IND (investigational new drug) filing later this year." said John Petrovich, Calando's chief executive officer.

Both the drugs are in the development stage.

ARWR closed Monday's trading at $5.4500, up $0.1410 on a volume of 255K shares.

[HuginundMunin]

Das Ding geht ab wie eine Rakete und niemanden interessierts auf Wallstreet Online.

Hey, Nanotechnologie ist die Zukunft.

[Nanostart]

Moin, moin,

klar bin ich investiert. Ich freue mich seit wochen das Ding geht ab wie die Post.
Habe fast durch Zufall zum niedrigsten Kurs gekauft in € unter 3,00.
Sieht wirklich Gut aus. Die Dinger gebe ich nie wieder her.
Alleine die Beteiligung an CNI ist der Hammer.

Parallel zum Kurs steigen auch stätig die Umsätze, also alles bestens.

Gruß

[HuginundMunin]

Antwort auf Beitrag Nr.: 29.008.164 von Nanostart am 26.04.07 08:33:32

Hammernews: Heute wieder nach Norden

http://www.finanznachrichten.de/nachrichten-2007-05/artikel-…

[HuginundMunin]

Antwort auf Beitrag Nr.: 29.269.494 von HuginundMunin am 11.05.07 14:40:00

heute fast 9 % Plus

[BERNDDD]

der Chart sieht gut aus...........
bin sauer, das ich vor Monaten nicht eingestiegen bin.